Food News and Research

RSS

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

10 Apr 2014

Novel discovery could lead to new therapy to combat obesity, diabetes

By manipulating a biochemical process that underlies cells' energy-burning abilities, investigators at Beth Israel Deaconess Medical Center have made a novel discovery that could lead to a new therapy to combat obesity and diabetes.

10 Apr 2014

LabStyle Innovations, FatSecret partner for Dario Diabetes Management Solution

LabStyle Innovations Corp., developer of the Dario Diabetes Management Solution, today announced a partnership with the world's leading global nutrition data application, FatSecret.

9 Apr 2014

First Edition: April 9, 2014

Today's headlines include coverage of the release of Medicare billing and utilization data, as well as early insights into who enrolled in health coverage as a result of the health law.

9 Apr 2014

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Forest Laboratories, Inc. and Almirall, S.A. today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol.

9 Apr 2014

Food experts to discuss pros and cons of GM crops at Food Integrity and Traceability Conference

One of the world's most contentious food issues - Genetically Modified (GM) crops - will be debated by some of the world's leading authorities on the subject at Queen's University Belfast today (Wednesday day 9 April).

9 Apr 2014

Viewpoints: A 'misguided' debate; trying to figure out who's uninsured; the safety net for the middle class

Supporters of Obamacare are celebrating that the law is not an unmitigated disaster, just a mitigated one. As enrollment closed (for most) on March 31, the system passed 7 million exchange sign-ups.

9 Apr 2014

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

A $1.92 million grant from the National Institutes of Health (NIH) was awarded to a research team that focuses on new approaches for treatment of relapsed pediatric acute myelogenous leukemia (rAML), led by Yang Liu, PhD, Bothworth Chair and Director of the Center for Cancer and Immunology Research (CCIR) at Children's Research Institute of Children's National Health System, and Reuven Schore, MD, member of CCIR and attending physician in the Leukemia & Lymphoma Program of the Division of Oncology of the Center for Cancer and Blood Disorders.

9 Apr 2014

Senomyx collaborates with PepsiCo to identify salt flavors with modifying properties

Senomyx, Inc., a leading company in using proprietary taste science technologies to discover, develop and commercialize novel flavor ingredients for the food, beverage and flavor industries, announced today that it has entered into a new collaborative agreement with PepsiCo, Inc. related to Senomyx's Salt Taste Program.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Hospital kitchens remain source of transmission for multi-drug resistant bacteria

After handling raw poultry, hands of food preparers and cutting boards remain a source of transmission for multi-drug resistant bacteria, such as E. coli that produce extended-spectrum beta-lactamases (ESBLs).

9 Apr 2014

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes.

9 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.

8 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

Food safety experts to deliver presentations at Food Integrity and Traceability Conference

Food safety experts from around the world will be at Queen's University Belfast this week (8-10 April) to highlight current and emerging threats to the integrity of the food chain.

8 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance).

8 Apr 2014

Medical professionals offer tips for preventing accidents during spring cleaning

Medical professionals at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe this spring while participating in spring cleaning.

8 Apr 2014

Food News and Research

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Novel discovery could lead to new therapy to combat obesity, diabetes

LabStyle Innovations, FatSecret partner for Dario Diabetes Management Solution

First Edition: April 9, 2014

Forest Laboratories, Almirall receive feedback from FDA regarding fixed dose combination of aclidinium/formoterol

Food experts to discuss pros and cons of GM crops at Food Integrity and Traceability Conference

Viewpoints: A 'misguided' debate; trying to figure out who's uninsured; the safety net for the middle class

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

Senomyx collaborates with PepsiCo to identify salt flavors with modifying properties

Researchers identify novel compound effective against drug-resistant lung cancer

Hospital kitchens remain source of transmission for multi-drug resistant bacteria

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Food safety experts to deliver presentations at Food Integrity and Traceability Conference

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Medical professionals offer tips for preventing accidents during spring cleaning

Understanding cultivated meat and its global potential eBook

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Latest News